News Search Results
Apr 22, 2025, 07:00 ET Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101 and Appoints Keith Orford, MD, PhD, as Chief Medical Officer
with the appointment of Keith Orford, MD, PhD, as CMO. Dr. Orford's proven track record as a physician, scientist, and executive leader at several biotechnology companies will support Tagworks' position as a leader and innovator in cancer drug development. "We are pleased to welcome Keith and look
More news about: Tagworks Pharmaceuticals BV
Apr 22, 2025, 06:00 ET Danaher Reports First Quarter 2025 Results
C Impairment charges related to a facility in the Biotechnology segment recorded in the three-month period ended March 28, 2025 ($15 million pretax as reported in this line item, $11 million after-tax).
More news about: Danaher Corporation
Apr 22, 2025, 05:45 ET Sana Biotechnology, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Apr 22, 2025, 02:00 ET Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in Combination with Rituximab
PARIS, April 22, 2025 /PRNewswire/ -- Onward Therapeutics SA, a biotechnology company dedicated to advancing innovative cancer immunotherapies, announced that its subsidiary, Emercell SAS, has received Investigational Medicinal
More news about: Onward Therapeutics
Apr 21, 2025, 17:31 ET Roche's HEMLIBRA Achieves Significant Uptake Across Key Hemophilia A Markets | DelveInsight
clot formation and minimize or prevent bleeding episodes. Initially, FVIII replacement was sourced from whole blood and plasma, but advances in biotechnology led to the development of recombinant FVIII (rFVIII) therapies, significantly enhancing disease management by offering more precise and efficient
More news about: DelveInsight Business Research, LLP
Apr 21, 2025, 10:15 ET Cell Based Assays Market worth US$27.55 billion by 2030 with 9.1% CAGR | MarketsandMarkets™
(US). Merck KGaA (Germany): is a leading provider of solutions and services for research, biotechnology, and pharmaceutical drug development and production in the global life sciences industry. The company offers tools, services, and digital platforms
More news about: MarketsandMarkets
Apr 21, 2025, 08:30 ET BGM Group Acquires Wonder Dragon to Accelerate "Healthcare" Strategy
platform. Mr. Xin Chen, CEO of BGM Group, commented: "Wonder Dragon's Qingzhuan dark tea resources, combined with our biotechnology platform, will significantly advance our medicinal tea product development and distribution. By leveraging our technological expertise, we intend
More news about: BGM Group Ltd
Apr 21, 2025, 08:24 ET BIO Asia-Taiwan Kicks Off on an Expanded Scale July 23
Zone, participating companies include PharmaEssentia, MycoMagic Biotechnology, Golden Biotechnology, Foresee Pharmaceuticals, Wendy International, Formosa Pharmaceuticals, AP Biosciences, TAHO Pharmaceuticals, Charsire Biotechnology, Elixiron Immunotherapeutics, BoYen Therapeutics, WCC Biomedical, Transin
More news about: Taiwan Bio Industry Organization
Apr 21, 2025, 08:00 ET Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals
approximately 60.6 million shares on a fully-diluted basis. About Aerovate Therapeutics, Inc. Aerovate Therapeutics is a biotechnology company that was focused on improving the lives of patients with rare cardiopulmonary disease. For more information, please visit
More news about: Aerovate Therapeutics
Apr 21, 2025, 07:00 ET SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, both dates inclusive
More news about: THE ROSEN LAW FIRM, P. A.
Apr 21, 2025, 07:00 ET Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension
SHANGHAI, April 21, 2025 /PRNewswire/ -- Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for RN1871, a small interfering
More news about: Rona Therapeutics
Apr 21, 2025, 07:00 ET Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension
SHANGHAI, April 21, 2025 /PRNewswire/ -- Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for RN1871, a small interfering
More news about: Rona Therapeutics
Apr 21, 2025, 07:00 ET Acepodia Presents Preclinical Data on Antibody-Dual-Drugs Conjugation (AD2C) technology at AACR Annual Meeting 2025
therapeutic payloads using bioorthogonal click chemistry. About AcepodiaAcepodia (6976.TT) is a clinical-stage biotechnology company headquartered in Taipei and Alameda, California, advancing innovative
More news about: Acepodia Inc.
Apr 21, 2025, 07:00 ET CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program
New Jersey Technology Business Tax Certificate Transfer Program enables approved Technology and Biotechnology Businesses with Net Operating Losses to sell their Unused Net Operating Loss (NOL) and Unused Research and Development Tax Credits (R&D Tax
More news about: CytoSorbents Corporation
Apr 21, 2025, 06:07 ET NASA Science, Cargo Launch on 32nd SpaceX Resupply Station Mission
investigations conducted aboard the orbiting laboratory each year in the areas of biology and biotechnology, physical sciences, and Earth and space science. Such research benefits humanity and helps lay the groundwork for future human exploration through
More news about: NASA
Apr 21, 2025, 05:45 ET The Gross Law Firm Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
April 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
More news about: The Gross Law Firm
Apr 18, 2025, 05:45 ET Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc.(SANA) of a Class Action Lawsuit and an Upcoming Deadline
April 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Apr 17, 2025, 20:00 ET 鈦隼生技が第一金証券と提携し、上場支援計画を開始
竹北市、2025年4月18日/PRNewswire/ -- 鈦隼生物科技股份有限公司（Brain Navi Biotechnology Co., Ltd.、以下「ブレインナビ」と略称）は、第一金証券（本社 高雄市）とIPO支援契約を締結し、正式に上場支援計画を開始しました。これにより、資本市場への進出を目指します。
More news about: Brain Navi
Apr 17, 2025, 11:03 ET James Gromann Joins Rubin and Rudman's Real Estate Practice Group
Rubin and Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin and Rudman
Apr 17, 2025, 11:00 ET Scion Life Sciences Expands Team with Appointment of Three Venture Partners
April 17, 2025 /PRNewswire/ -- Scion Life Sciences ("Scion"), a venture capital firm dedicated to founding and building exceptional biotechnology companies, today announced the appointment of Lalo Flores, Ph.D., Huw Nash, Ph.D.
More news about: Scion Life Sciences
Apr 17, 2025, 10:00 ET Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board
pharmaceutical company acquired by Sanofi Pasteur, and Transmolecular, Inc., a biotechnology company developing cancer diagnostics and treatments. He has also held senior positions in a number of pharmaceutical and biotechnology companies, including Morphotek and Vicuron Pharmaceuticals, and currently serves
More news about: Monument Therapeutics
Apr 17, 2025, 10:00 ET Lilly confirms date and conference call for first-quarter 2025 financial results announcement
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Apr 17, 2025, 09:00 ET BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET
https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call. About BioMarinBioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The
More news about: BioMarin Pharmaceutical Inc.
Apr 17, 2025, 07:30 ET Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange
More news about: Palatin Technologies, Inc.
Apr 17, 2025, 07:15 ET Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders
thriving in one of the most challenging biotechnology environments in a generation: Delivered total stockholder returns of 267% over the past five years, far exceeding the performance of the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index3.Achieved
More news about: Dynavax Technologies